HMGB1 and diabetes mellitus: Interestingly, treatment with LPLI decreases the diabetes-induced transcription of HMGB1 and RAGE, with reductions of AGE, RAGE, HMGB1 and TNF-α protein expression, possibly down-regulating NF-κB in diabetic SMGs, indicating that LPLI has a potent anti-inflammatory effect.